IN THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the application. The following amendments are without prejudice and do not constitute an admission regarding the patentability of the amended subject matter and should not be so construed.

Claims 1 – 236. (Cancelled)

Claim 237. (Currently amended) A pharmaceutical composition for oral administration in a solid dosage from comprising:

(a) about 5 mg to about 100 mg of non-enteric coated omeprazole;

(b) about 250 mg to about 4000 mg of a buffering agent selected from the group consisting of sodium bicarbonate, ~~magnesium hydroxide, magnesium oxide, calcium hydroxide, calcium carbonate,~~ calcium acetate, calcium lactate, calcium glycerophosphate and mixtures thereof; and

(c) about 12 mg to about 66 mg of a disintegrant.

Claim 238. (Previously presented) The composition of claim 237, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule, or a chewable tablet.

Claim 239. (Previously presented) The pharmaceutical composition of claim 237, wherein the disintegrant is croscarmellose sodium.

Claim 240. (Previously presented) The composition of claim 239, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule, or a chewable tablet.

Claim 241. (Previously presented) The pharmaceutical composition of claim 237, wherein the buffering agent is present in an amount of about 36 wt-% to about 97 wt-%.

Claim 242. (Previously presented) The composition of claim 237, further comprising enteric coated omeprazole.

Claim 243. (Previously presented) The composition of claim 240, wherein the omeprazole is present in the composition in an amount of about 20 mg.

Claim 244. (Previously presented) The composition of claim 240, wherein the omeprazole is present in the composition in an amount of about 40 mg.

Claim 245. (Previously presented) The composition of claim 240, further comprising at least one pharmaceutically acceptable excipient selected from the group consisting of a binder, a lubricant, and a parietal cell activator.

Claim 246. (Previously presented) The composition of claim 237, wherein the buffering agent further comprises at least one additional buffering agent.

Claim 247. (Currently amended) The composition of claim 246, wherein the at least one additional buffering agent is selected from magnesium hydroxide, calcium carbonate, calcium hydroxide or magnesium oxide.

Claim 248. (Previously presented) The composition of claim 237, wherein the buffering agent is sodium bicarbonate.

Claim 249. (Previously presented) The composition of claim 237, wherein the sodium bicarbonate is present in the composition in a total amount of about 10 mEq to about 70 mEq.

Claim 250. (Previously presented) The composition of claim 237, wherein the sodium bicarbonate is present in the composition in a total amount of about 7 mEq to about 25 mEq.

Claim 251. (Previously presented) The composition of claim 237, wherein the sodium bicarbonate is present in the composition in a total amount of about 20 mEq to about 40 mEq.

Claim 252. (Previously presented) The composition of claim 237, wherein the sodium bicarbonate is present in the composition in a total amount of about 4 mEq to about 30 mEq.

Claim 253. (Previously presented) The composition of claim 237, wherein the solid dosage form is non-enteric coated.

Claim 254. (Currently amended) A pharmaceutical composition for oral administration in a solid dosage form comprising:

(a) about 15mg to about 80 mg of non-enteric coated omeprazole or an isomer of omeprazole, or an ester, amide, free base or salt thereof;

(b) about 56 wt-% to about 97 wt-% of a buffering agent selected from the group consisting of sodium bicarbonate, ~~magnesium hydroxide, magnesium oxide, calcium hydroxide, calcium carbonate,~~ calcium acetate, calcium lactate, calcium glycerophosphate and mixtures thereof; and

(c) about 1.3 wt-% to about 3.8 wt-% of a disintegrant selected from a group consisting of: croscarmellose sodium, pregelatinized starch, cellulosic materials and mixtures thereof.

Claim 255. (Previously presented) The composition of claim 254, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule, or a chewable tablet.

Claim 256. (Previously presented) The pharmaceutical composition of claim 255, wherein the disintegrant is croscarmellose sodium.

Claim 257. (Previously presented) The composition of claim 254, wherein the solid dosage form is selected from the group consisting of a tablet, a capsule, or a chewable tablet.

Claim 258. (Previously presented) The pharmaceutical composition of claim 254, wherein the omeprazole is present in an amount of about 1.2-2.9 wt-%.

Claim 259. (Previously presented) The composition of claim 254, further comprising enteric coated omeprazole.

Claim 260. (Previously presented) The composition of claim 255, wherein the omeprazole is present in the composition in an amount of about 20 mg.

Claim 261. (Previously presented) The composition of claim 255, wherein the omeprazole is present in the composition in an amount of about 40 mg.

Claim 262. (Previously presented) The composition of claim 255, further comprising at least one pharmaceutically acceptable excipient selected from the group consisting of a binder, a lubricant, and a parietal cell activator.

Claim 263. (Previously presented) The composition of claim 254, wherein the buffering agent further comprises at least one additional buffering agent.

Claim 264. (Currently amended) The composition of claim 26, wherein the at least one additional buffering agent is selected from magnesium hydroxide, calcium carbonate, calcium hydroxide or magnesium oxide.

Claim 265. (Previously presented) The composition of claim 254, wherein the sodium bicarbonate is present in the composition in a total amount of about 250 mg to about 4000 mg.

Claim 266. (Previously presented) The composition of claim 254, wherein the sodium bicarbonate is present in the composition in a total amount of about 10 mEq to about 70 mEq.

Claim 267. (Previously presented) The composition of claim 254, wherein the sodium bicarbonate is present in the composition in a total amount of about 7 mEq to about 25 mEq.

Claim 268. (Previously presented) The composition of claim 254, wherein the magnesium hydroxide is present in the composition in a total amount of about 20 mEq to about 40 mEq.

Claim 269. (Previously presented) The composition of claim 254, wherein the sodium bicarbonate is present in the composition in a total amount of about 4 mEq to about 30 mEq.

Claim 270. (Previously presented) The composition of claim 254, wherein the solid dosage form is non-enteric coated.

Claim 271. (Previously presented) The composition of claim 254, wherein at least some of the omeprazole is micronized.

Claim 272. (Previously presented) The composition of claim 237, wherein at least some of the omeprazole is micronized.

Claim 273. (Previously presented) A solid oral pharmaceutical composition comprising:

(a) non-enteric coated omeprazole in an amount of about 2 mg to about 100 mg; and

(b) a buffering agent comprising about 0.375 mEq to about 0.75 mEq of sodium bicarbonate per mg of omeprazole;

wherein the buffering agent is present in the solid oral pharmaceutical composition in an amount sufficient to permit absorption of a therapeutically effective amount of the non-enteric coated omeprazole after oral administration to a subject.

Claim 274. (Previously presented) The solid oral pharmaceutical composition of claim 273, wherein the omeprazole is present in an amount of about 20 mg.

Claim 275. (Previously presented) The solid oral pharmaceutical composition of claim 273, wherein the omeprazole is present in an amount of about 40 mg.

Claim 276. (Previously presented) The solid oral pharmaceutical composition of claim 273, wherein said solid oral pharmaceutical composition is in a dosage form selected from the group consisting of a tablet, a capsule, an effervescent powder, pellets and granules.

Claim 277. (Previously presented) The solid oral pharmaceutical composition of claim 276, wherein the dosage form is a capsule.

Claim 278. (Previously presented) The solid oral pharmaceutical composition of claim 276, wherein the dosage form is a tablet.

Claim 279. (Previously presented) The solid oral pharmaceutical composition of claim 273, wherein the buffering agent is sodium bicarbonate.

Claim 280. (Previously presented) The solid oral pharmaceutical composition of claim 273, wherein the omeprazole is micronized.

Claim 291. (Previously presented) The solid oral pharmaceutical composition of claim 237, wherein the dosage from is a capsule.

Claim 292. (Previously presented) The solid oral pharmaceutical composition of claim 237, wherein the dosage from is a chewable tablet.

Claim 293. (Previously presented) The solid oral pharmaceutical composition of claim 237, wherein the dosage from is a tablet.

Claim 294. (Previously presented) The solid oral pharmaceutical composition of claim 254, wherein the dosage from is a capsule.

Claim 295. (Previously presented) The solid oral pharmaceutical composition of claim 254, wherein the dosage from is a chewable tablet.

Claim 296. (Previously presented) The solid oral pharmaceutical composition of claim 254, wherein the dosage from is a tablet.

Claim 297. (Previously presented) The solid oral pharmaceutical composition of claim 273, wherein the dosage from is a capsule.

Claim 298. (Previously presented) The solid oral pharmaceutical composition of claim 273, wherein the dosage from is a chewable tablet.

Claim 299. (Previously presented) The solid oral pharmaceutical composition of claim 273, wherein the dosage from is a tablet.